Related Experiment Video
Updated: Feb 23, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Vincristine, Irinotecan, and Bevacizumab in Relapsed Wilms Tumor With Diffuse Anaplasia
Amalia Schiavetti1, Giulia Varrasso1, Paola Collini2
1Department of Pediatrics, "Sapienza" University of Rome, Rome.
Abstract:
The prognosis of relapsed Wilms tumor (WT) with diffuse anaplasia is dismal, therefore, novel therapeutic strategies need to be explored. We reported on 2 consecutive cases with relapsed anaplastic WT who presented a partial response after 2 courses of vincristine, irinotecan, and bevacizumab association. This regimen may have a role in the treatment of patients with anaplastic advanced WT.
Related Concept Videos
Treatment Resistant Cancers
Tumor Immunotherapy
Drugs that Destabilize Microtubules
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...

